康泰生物跌2.01%，成交额1.57亿元，主力资金净流出1282.00万元

Company Overview - 康泰生物 is a company based in Shenzhen, Guangdong, established on September 8, 1992, and listed on February 7, 2017. The company specializes in the research, production, and sales of human vaccines [1] - The main business revenue composition includes non-immunization program vaccines (93.70%), immunization program vaccines (3.71%), and others (2.59%) [1] Financial Performance - As of June 30, 2025, 康泰生物 achieved a revenue of 1.392 billion yuan, representing a year-on-year growth of 15.81%. However, the net profit attributable to shareholders was 37.53 million yuan, a decrease of 77.30% compared to the previous period [2] - The company has cumulatively distributed 1.765 billion yuan in dividends since its A-share listing, with 525 million yuan distributed over the past three years [3] Stock Performance - On August 28, 康泰生物's stock price decreased by 2.01%, trading at 18.53 yuan per share, with a total market capitalization of 20.697 billion yuan [1] - Year-to-date, the stock price has increased by 8.62%, with a 0.16% decline over the last five trading days, a 6.37% increase over the last 20 days, and a 28.06% increase over the last 60 days [1] Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 1.84% to 61,500, with an average of 14,634 circulating shares per person, an increase of 3.48% [2] - The top ten circulating shareholders include major funds such as 易方达创业板ETF and 招商国证生物医药指数A, with some holdings decreasing while others, like 南方中证500ETF, increased [3]